港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

恒瑞医药

46.300

-1.900-3.94%

成交量：867.63万

成交额：4.12亿

市值：3,072.93亿

市盈率：33.65

高：49.000

开：48.300

低：46.140

收：48.200

52周最高：94.869

52周最低：46.140

股本：66.37亿

香港流通股本：2.58亿

量比：1.98

换手率：3.36%

股息：0.23

股息率：0.50%

每股收益(LYR):1.376

净资产收益率：12.46%

总资产收益率：7.02%

市净率：4.09

市盈率(LYR):33.65

市销率: 8.41

数据加载中...

总览公司新闻资讯公告

异动解读｜恒瑞医药盘中下跌3.03%，交银国际下调目标价叠加中报承压

【券商聚焦】交银国际维持恒瑞医药（01276）中性评级指存量品种或持续承压

恒瑞医药（01276）增长结构生变：第二曲线提速全球价值释放

《大行》汇丰研究降恒瑞医药(01276.HK)目标价至73.7元维持“买入”评级

阿斯达克财经

《股市简讯》中国恒瑞医药港股早盘挫4.1%创新低，续受业绩增速放缓拖累

异动解读｜恒瑞医药盘中下跌3.18%，中报扣非净利大降延续抛压

恒瑞医药(01276)出现大手卖出11.68万股，成交价$48.0，涉资560.64万

阿斯达克财经

恒瑞医药的拐点，藏在四个信号里

创新药占比突破63%，恒瑞医药正在切换估值坐标

恒瑞医药(01276.HK)SHR-8203注射液获准开展临床试验

阿斯达克财经

恒瑞医药同日公告：一款1类新药获批上市，三款创新药齐获临床批准

每日经济新闻

恒瑞医药自主研发1类创新药利康帕泛富马酸（HRS-5965）胶囊获国家药监局批准上市

恒瑞医药获批开展HRS-3095片ITP及AIHA适应症临床试验

恒瑞医药(01276.HK) ：SHR-7012 注射液拟用于治疗皮肤型红斑狼疮获批开展临床试验

恒瑞医药获批开展SHR-7012注射液临床试验

恒瑞医药(01276)获批开展SHR-8203注射液晚期实体瘤临床试验

恒瑞医药(01276.HK)：SHR-8203 注射液获药物临床试验批准通知书

恒瑞医药富马酸立康可泮胶囊获药品注册批准

恒瑞医药：子公司3款药物获批临床

恒瑞医药：HRS-3095片获临床试验批准

南方财经网

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/01276/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01276","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":46.3,"timestamp":1787543560411,"preClose":48.2,"halted":0,"volume":8676300,"delay":0,"changeRate":-0.03941908713692958,"floatShares":258000000,"shares":6637000000,"eps":1.3757724749929445,"marketStatus":"交易中","change":-1.9,"latestTime":"08-24 11:52:44","open":48.3,"high":49,"low":46.14,"amount":412135273,"amplitude":0.059336,"askPrice":46.34,"askSize":1200,"bidPrice":46.3,"bidSize":3200,"shortable":3,"etf":0,"ttmEps":1.356756501207237,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1787544000000},"marketStatusCode":2,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":48.2,"dividendRate":0.00504,"openAndCloseTimeList":[[1787535000000,1787544000000],[1787547600000,1787558400000]],"volumeRatio":1.981842,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":46.95,"timestamp":1787542199000,"preClose":47.74,"halted":0,"volume":51207500,"delay":0,"premium":"-15.42"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","floatShares":258000000,"roa":"7.02%","roe":"12.46%","lyrEps":1.375772,"volumeRatio":1.981842,"shares":6637000000,"dividePrice":0.233182,"high":49,"amplitude":0.059336,"preClose":48.2,"low":46.14,"week52Low":46.14,"pbRate":"4.09","psRate":"8.41","week52High":94.869,"institutionHeld":0,"latestPrice":46.3,"committee":0.454545,"eps":1.3757724749929445,"divideRate":0.005036,"volume":8676300,"delay":0,"ttmEps":1.356756501207237,"open":48.3,"prevYearClose":71.002,"prevWeekClose":48.2,"prevMonthClose":57.1,"prevQuarterClose":57.85,"fiveDayClose":53.7,"twentyDayClose":57.05,"sixtyDayClose":58.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01276\",params:#limit:5,,,undefined,":[{"date":"2026-08-19","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787103000000,"name":null,"time":"","dateTimestamp":1787068800000,"actualEps":null},{"date":"2026-04-29","symbol":"01276","amount":0.22828,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2026-04-30","defaultRemindTime":1777426200000,"name":"恒瑞医药","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-27","payableDate":"2026-04-30","currency":"HKD","dateTimestamp":1777392000000,"payDate":"2026-05-27"},{"date":"2026-04-22","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1776821400000,"name":null,"time":"","dateTimestamp":1776787200000,"actualEps":null},{"date":"2026-03-26","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null},{"date":"2025-10-28","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1761615000000,"name":null,"time":"","dateTimestamp":1761580800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01276\",market:\"HK\",,,undefined,":[{"executeDate":"2026-04-29","recordDate":"2026-04-30","paymentDate":"2026-05-27","value":0.22828,"currency":"HKD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01276\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.5455,"hold":0.1818,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5455,"analysts":11,"updateTime":1786723200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01276\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01276","date":"2026-08-21","current":35.500363,"percent":0.064935,"low":37.44534,"twenty":44.408765,"median":52.120101,"eighty":57.75211,"high":65.582363,"avg":51.795451,"sd":7.046662,"marketCap":366558497066.13},"quantilePoints":[{"date":"2025-05-23","current":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"marketCap":390693388207.53},{"date":"2025-05-30","current":53.015805,"twenty":51.822085,"median":52.540895,"eighty":52.926837,"marketCap":395731540422.24},{"date":"2025-06-06","current":52.120101,"twenty":52.130014,"median":52.555929,"eighty":53.075252,"marketCap":390038198012.59},{"date":"2025-06-13","current":52.209491,"twenty":52.177631,"median":52.691227,"eighty":53.357137,"marketCap":390861633032.23},{"date":"2025-06-20","current":50.172412,"twenty":51.591196,"median":52.469796,"eighty":53.075252,"marketCap":374874997562.85},{"date":"2025-06-27","current":50.314776,"twenty":50.363569,"median":52.169666,"eighty":53.013533,"marketCap":376991477472.78},{"date":"2025-07-04","current":51.666141,"twenty":50.343584,"median":52.120101,"eighty":53.004446,"marketCap":387134991658.26},{"date":"2025-07-11","current":55.507007,"twenty":50.44351,"median":52.13337,"eighty":53.090114,"marketCap":415495681161.23},{"date":"2025-07-18","current":57.272274,"twenty":50.582121,"median":52.209491,"eighty":54.057606,"marketCap":428373566715.29},{"date":"2025-07-25","current":54.897923,"twenty":50.594414,"median":52.555929,"eighty":55.711415,"marketCap":412107620053.2},{"date":"2025-08-01","current":59.731878,"twenty":50.855059,"median":52.994419,"eighty":55.972407,"marketCap":445624526286.47},{"date":"2025-08-08","current":59.478715,"twenty":51.107295,"median":53.05296,"eighty":56.541585,"marketCap":444845815775.64},{"date":"2025-08-15","current":61.917611,"twenty":51.356483,"median":53.519848,"eighty":59.478715,"marketCap":462392609292.46},{"date":"2025-08-22","current":58.782188,"twenty":51.569512,"median":54.477764,"eighty":60.15932,"marketCap":470428104569.66},{"date":"2025-08-29","current":59.85298,"twenty":51.666141,"median":55.691374,"eighty":59.937003,"marketCap":481284287403.35},{"date":"2025-09-05","current":65.582363,"twenty":51.677932,"median":55.770266,"eighty":60.732448,"marketCap":526832269752.24},{"date":"2025-09-12","current":62.481332,"twenty":51.8337,"median":55.972407,"eighty":61.285609,"marketCap":502824785657.99},{"date":"2025-09-19","current":63.179889,"twenty":52.120101,"median":56.254853,"eighty":61.852995,"marketCap":508085671393.42},{"date":"2025-09-26","current":63.528382,"twenty":52.146639,"median":56.965096,"eighty":62.270337,"marketCap":509562668601.01},{"date":"2025-10-03","current":64.989073,"twenty":52.165061,"median":57.272274,"eighty":62.504861,"marketCap":522523002865.02},{"date":"2025-10-10","current":61.782766,"twenty":52.193561,"median":59.039802,"eighty":62.657943,"marketCap":496019912951.91},{"date":"2025-10-17","current":58.903713,"twenty":52.323014,"median":59.170669,"eighty":62.619084,"marketCap":472537436949.31},{"date":"2025-10-24","current":59.187086,"twenty":52.484015,"median":59.039802,"eighty":62.52839,"marketCap":474983377696.11},{"date":"2025-10-31","current":57.072441,"twenty":52.552922,"median":59.021138,"eighty":62.417499,"marketCap":465758305542.93},{"date":"2025-11-07","current":54.713071,"twenty":52.619069,"median":58.881843,"eighty":62.304573,"marketCap":446224987036.64},{"date":"2025-11-14","current":55.883072,"twenty":52.812504,"median":58.231971,"eighty":62.27542,"marketCap":457058673340.29},{"date":"2025-11-21","current":52.805265,"twenty":52.880927,"median":57.030538,"eighty":62.209511,"marketCap":431684582485.14},{"date":"2025-11-28","current":55.237621,"twenty":52.99843,"median":56.630614,"eighty":62.069705,"marketCap":453209419829.34},{"date":"2025-12-05","current":54.841023,"twenty":53.00899,"median":56.437545,"eighty":61.965159,"marketCap":450729029423.46},{"date":"2025-12-12","current":56.212257,"twenty":53.045529,"median":56.385682,"eighty":61.891765,"marketCap":462853512587.19},{"date":"2025-12-19","current":54.083493,"twenty":53.045529,"median":56.227363,"eighty":61.831221,"marketCap":446374731108.34},{"date":"2025-12-24","current":54.414957,"twenty":53.090114,"median":56.103073,"eighty":61.798561,"marketCap":450509359276.9},{"date":"2026-01-02","current":53.078544,"twenty":53.065996,"median":55.972407,"eighty":61.785925,"marketCap":441174507319.22},{"date":"2026-01-09","current":56.743223,"twenty":53.0878,"median":56.0944,"eighty":61.695241,"marketCap":472808676524.34},{"date":"2026-01-16","current":55.187351,"twenty":53.304215,"median":56.103073,"eighty":61.405393,"marketCap":461338821289.95},{"date":"2026-01-23","current":52.546341,"twenty":53.0878,"median":56.076447,"eighty":61.296167,"marketCap":438839874056.97},{"date":"2026-01-30","current":51.677141,"twenty":52.994149,"median":55.908509,"eighty":61.278475,"marketCap":433553740508.2},{"date":"2026-02-06","current":50.918226,"twenty":52.680723,"median":55.839154,"eighty":61.101743,"marketCap":428270226283.58},{"date":"2026-02-13","current":51.771686,"twenty":52.512455,"median":55.711415,"eighty":60.890064,"marketCap":437949787160.49},{"date":"2026-02-20","current":51.752043,"twenty":52.351169,"median":55.691374,"eighty":60.824953,"marketCap":437153052005.04},{"date":"2026-02-27","current":50.215456,"twenty":52.151244,"median":55.507566,"eighty":60.720339,"marketCap":428825318404.97},{"date":"2026-03-06","current":49.335298,"twenty":51.80347,"median":55.280584,"eighty":60.654676,"marketCap":417912584744.19},{"date":"2026-03-13","current":48.90444,"twenty":51.75217,"median":55.201025,"eighty":60.572606,"marketCap":416170839186.33},{"date":"2026-03-20","current":48.948437,"twenty":51.671435,"median":55.086674,"eighty":60.515374,"marketCap":414967977646.95},{"date":"2026-03-27","current":47.483832,"twenty":51.400677,"median":54.94883,"eighty":60.443129,"marketCap":414588875872.42},{"date":"2026-04-02","current":49.302243,"twenty":51.107295,"median":54.905743,"eighty":60.227005,"marketCap":432534434303.11},{"date":"2026-04-10","current":49.055344,"twenty":50.995993,"median":54.897923,"eighty":60.186394,"marketCap":433687668394.36},{"date":"2026-04-17","current":48.417764,"twenty":50.589497,"median":54.65026,"eighty":60.143018,"marketCap":428230701835.75},{"date":"2026-04-24","current":45.835792,"twenty":50.342877,"median":54.475147,"eighty":60.015062,"marketCap":426879682872.04},{"date":"2026-04-30","current":44.026312,"twenty":50.285416,"median":54.355253,"eighty":59.903394,"marketCap":410132737659.64},{"date":"2026-05-08","current":43.161515,"twenty":50.207478,"median":54.262074,"eighty":59.804539,"marketCap":403472171949.3},{"date":"2026-05-15","current":44.128138,"twenty":49.985706,"median":54.115335,"eighty":59.70386,"marketCap":413593092820.6},{"date":"2026-05-22","current":41.244553,"twenty":49.583265,"median":53.983854,"eighty":59.631568,"marketCap":385683097978.4},{"date":"2026-05-29","current":40.98659,"twenty":49.34142,"median":53.840414,"eighty":59.564678,"marketCap":384603594259.51},{"date":"2026-06-05","current":38.394132,"twenty":49.063316,"median":53.633194,"eighty":59.459458,"marketCap":360799766229.36},{"date":"2026-06-12","current":39.515262,"twenty":48.81081,"median":53.517715,"eighty":59.36625,"marketCap":371084155232.86},{"date":"2026-06-18","current":39.444808,"twenty":48.417764,"median":53.467699,"eighty":59.301536,"marketCap":371311256576.18},{"date":"2026-06-26","current":39.60241,"twenty":47.951326,"median":53.090114,"eighty":59.187086,"marketCap":370974287810.31},{"date":"2026-07-03","current":44.319925,"twenty":47.638943,"median":53.015805,"eighty":59.069259,"marketCap":415476044901.86},{"date":"2026-07-10","current":45.319748,"twenty":47.348429,"median":52.993744,"eighty":59.024871,"marketCap":424327469311.14},{"date":"2026-07-17","current":43.189222,"twenty":46.151454,"median":52.805265,"eighty":58.96135,"marketCap":405818502739.33},{"date":"2026-07-24","current":43.433009,"twenty":45.632553,"median":52.604835,"eighty":58.912251,"marketCap":408200902707.63},{"date":"2026-07-31","current":43.935338,"twenty":45.29749,"median":52.543618,"eighty":58.877468,"marketCap":413706414238.87},{"date":"2026-08-07","current":44.394532,"twenty":45.008473,"median":52.339287,"eighty":58.813302,"marketCap":418841988303.56},{"date":"2026-08-14","current":42.6704,"twenty":44.628794,"median":52.189578,"eighty":58.452058,"marketCap":403085247281.44},{"date":"2026-08-21","current":40.686911,"twenty":44.408765,"median":52.120101,"eighty":57.75211,"marketCap":366558497066.13}],"updateTime":1787532822178},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01276\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1190257896","title":"异动解读｜恒瑞医药盘中下跌3.03%，交银国际下调目标价叠加中报承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1190257896","media":"行情直击","labels":[],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1190257896?lang=zh_cn&edition=fundamental","pubTime":"2026-08-24 10:41","pubTimestamp":1787539277,"startTime":"0","endTime":"0","summary":"8月24日，恒瑞医药盘中下跌3.03%，报46.74港元，成交额3.26亿港元。消息面上，交银国际当日发布研报，下调恒瑞医药DCF目标价至57港元，指出存量品种或持续承压，维持中性评级。该机构认为公司仿制药收入受地方集采影响同比下滑16%，肿瘤创新药增速放缓至2.6%，成熟品种竞争加剧及竞品集采降价构成压力，当前估值合理但后续潜在升幅有限。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"恒瑞医药盘中下跌，中报承压叠加目标价遭下调","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661242707","title":"【券商聚焦】交银国际维持恒瑞医药（01276）中性评级 指存量品种或持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2661242707","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661242707?lang=zh_cn&edition=fundamental","pubTime":"2026-08-24 10:17","pubTimestamp":1787537823,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，恒瑞医药 1H26收入同比下降2%至154.6亿元，其中产品销售增长2%。创新药收入同比+16%，占药品总销售额比重升至63%，其中非肿瘤创新药销售收入同比+74%，肿瘤创新药增长2.6%，增速放缓主因成熟品种竞争加剧或竞品集采降价带来压力。仿制药收入同比下滑16%，主要受存量大品种地方集采的影响。扣非归母净利润同比-12.7%至37.3亿元。该机构下调DCF目标价至57港元/54.6元人民币，后续潜在升幅有限，当前估值合理，维持中性评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989114","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","600276","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661243816","title":"恒瑞医药（01276）增长结构生变：第二曲线提速 全球价值释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2661243816","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661243816?lang=zh_cn&edition=fundamental","pubTime":"2026-08-23 20:58","pubTimestamp":1787489920,"startTime":"0","endTime":"0","summary":"8月19日，恒瑞医药交出了一份韧性十足的半年报成绩单。更值得关注的是，恒瑞的增长结构正在发生变化。上半年，公司非肿瘤创新药销售收入达25.45亿元，同比增长73.97%，占创新药销售收入的比重进一步提升至28.89%。上半年恒瑞医药研发投入46.05亿元，同比增长18.96%，占营收比重达29.8%。长期以来，市场对恒瑞医药的认知高度锚定于抗肿瘤领域。“NewCo”模式则构成全球价值释放的第二条路径。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828714.EUR","LU2488822045.USD","LU2097828557.USD","LU2097828631.EUR","LU2289578879.USD","LU1655091616.SGD","LU0359201885.HKD","BK0239","LU0405327494.USD","LU1580142542.USD","LU1023057109.AUD","LU1064130708.USD","LU0405327148.USD","LU1820825898.SGD","LU2097828474.EUR","LU1781817850.SGD","LU2580892862.HKD","BK1191","LU1997245094.SGD","LU1997244956.HKD","LU1064131003.USD","BK0188","LU2495084118.USD","BK0028","BK0183","BK0012","BK0196","600276","LU0359201612.USD","01276","LU2328871848.SGD","LU1997245177.USD","LU2580892789.USD","BK0060","LU1328615791.USD","LU1255011170.USD","LU1969619763.USD","LU2148510915.USD","LU0359202008.SGD","LU1146622755.USD","LU2097828805.USD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661263420","title":"《大行》汇丰研究降恒瑞医药(01276.HK)目标价至73.7元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2661263420","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661263420?lang=zh_cn&edition=fundamental","pubTime":"2026-08-21 15:57","pubTimestamp":1787299020,"startTime":"0","endTime":"0","summary":"汇丰研究发表报告指，恒瑞医药2026上半年业绩因政策不确定性及国内激烈竞争而低于市场预期。惟全面的全球管线III期进展有望支持股价重估。维持“买入”评级，目标价由88.5元降至73.7元。该行将恒瑞医药2026至2028年收入预测下调6%至10%，因国内激烈竞争及政策不确定性而削减产品销售预测。基于有效成本控制，将其2026至2028年销售费用下调2%至4%，同时因海外合作伙伴Kailera及BraveHeart于纳斯达克上市而调高公允价值收益。沽空资料截至 2026-08-21 12:25。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250603120312570_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250603120312570_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1539915/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1539915/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["03441","600276","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661256233","title":"《股市简讯》中国恒瑞医药港股早盘挫4.1%创新低，续受业绩增速放缓拖累","url":"https://stock-news.laohu8.com/highlight/detail?id=2661256233","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661256233?lang=zh_cn&edition=fundamental","pubTime":"2026-08-21 10:07","pubTimestamp":1787278055,"startTime":"0","endTime":"0","summary":"《股市简讯》中国恒瑞医药港股早盘挫4.1%创新低，续受业绩增速放缓拖累* 中国恒瑞医药A股600276.SS周五早盘一度跌3.9%，创两个月新低。* 其H股1276.HK则一度挫4.1%，创历史新低；上日该股暴跌9.6%。* 恒瑞医药近日公布业绩，称上半年净利润同比增长0.34%，上半年营收同比减1.94%。相比之下，2025年上半年其净利润同比增29.7%，营收同比增15.9%。（完）更多股市简讯请点选CN-CMN-HOT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nL4T44I044:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2543165471.USD","LU1997245094.SGD","LU0359202008.SGD","BK0188","LU1328615791.USD","LU1064130708.USD","LU1997245177.USD","LU0359201612.USD","LU2580892862.HKD","BK0060","LU0405327148.USD","LU2289578879.USD","LU2488822045.USD","600276","BK0183","LU1023057109.AUD","LU1064131003.USD","LU1255011170.USD","LU1781817850.SGD","LU2580892789.USD","LU2097828805.USD","LU1820825898.SGD","BK0196","LU1997244956.HKD","LU1146622755.USD","BK1191","01276","LU2097828631.EUR","BK0028","LU1655091616.SGD","LU2495084118.USD","BK0239","BK0012","LU2328871848.SGD","LU0359201885.HKD","LU2097828474.EUR","LU1580142542.USD","LU0405327494.USD","LU2148510915.USD","LU2097828557.USD","LU1969619763.USD","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180330781","title":"异动解读｜恒瑞医药盘中下跌3.18%，中报扣非净利大降延续抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1180330781","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180330781?lang=zh_cn&edition=fundamental","pubTime":"2026-08-21 09:41","pubTimestamp":1787276474,"startTime":"0","endTime":"0","summary":"8月21日，恒瑞医药盘中下跌3.18%，报48.06港元，成交额8345.8万港元，延续前一交易日跌势。消息面上，公司8月19日晚间披露半年报，营业收入154.56亿元，同比下降1.94%；扣非归母净利润37.30亿元，同比大幅下滑12.71%；经营活动现金流净额19.87亿元，同比骤降53.8%。虽然创新药销售收入88.09亿元同比增长16.4%，但仿制药收入同比下滑16.07%，对外许可收入同比降28.6%，主业盈利质量明显承压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"恒瑞医药盘中下跌，中报扣非净利大降","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661132256","title":"恒瑞医药(01276)出现大手卖出11.68万股，成交价$48.0，涉资560.64万","url":"https://stock-news.laohu8.com/highlight/detail?id=2661132256","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661132256?lang=zh_cn&edition=fundamental","pubTime":"2026-08-21 09:40","pubTimestamp":1787276400,"startTime":"0","endTime":"0","summary":"[大手成交]恒瑞医药(01276)在上午09:40出现大手卖出，成交量为11.68万，成交价为港币$48.0，涉资560.64万。至目前为止，股价跌3.343%，今日最高价为$49.66，而最低价为$48.0，总成交量为186.714万股，总成交金额港币$9.05千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145550868_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145550868_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2608211518/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2608211518/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1146622755.USD","LU1781817850.SGD","LU1997244956.HKD","LU2097828805.USD","LU2488822045.USD","LU1997245177.USD","LU2097828714.EUR","LU2148510915.USD","BK0012","LU1064130708.USD","BK0183","LU2289578879.USD","LU1580142542.USD","LU0359201885.HKD","LU0359201612.USD","BK0196","LU1255011170.USD","LU2543165471.USD","LU2097828474.EUR","LU0405327148.USD","LU2328871848.SGD","600276","LU2495084118.USD","BK0028","BK0188","LU1328615791.USD","LU2580892862.HKD","BK1191","LU1820825898.SGD","LU1997245094.SGD","LU2097828631.EUR","LU2580892789.USD","01276","LU0405327494.USD","LU2097828557.USD","LU1655091616.SGD","BK0239","LU1023057109.AUD","LU1969619763.USD","BK0060","LU1064131003.USD","LU0359202008.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661625759","title":"恒瑞医药的拐点，藏在四个信号里","url":"https://stock-news.laohu8.com/highlight/detail?id=2661625759","media":"虎嗅APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661625759?lang=zh_cn&edition=fundamental","pubTime":"2026-08-21 07:57","pubTimestamp":1787270220,"startTime":"0","endTime":"0","summary":"整体来看，恒瑞医药的业绩是承压的。这是2026年一季度恒瑞创新药销售收入45.26亿元，同比增长25.75%，到了上半年累计增速却回落至16.38%。2026年上半年，恒瑞创新药对外许可及合作收入约14.22亿元，同比下降28.6%，较去年同期减少约5.69亿元。所以，恒瑞当前正处于仿制药还未出清、创新药接棒尚需时间、BD收入确认存在脉冲波动的三重叠加期，即处于阵痛期。后续关注恒瑞生产场地整改的公告，以及是否再次提交“双艾”的上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2656195381&idx=3&sn=8dd47bbd50b3da1623f81dcc84710a63&chksm=6782cdd6fc51ebd554bfad9b8a2504cd61b31c0f07db8ce0bfb6e55032d63e80b5cbf2f6f0ee&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU1146622755.USD","LU1781817850.SGD","LU1997244956.HKD","LU2097828805.USD","LU2488822045.USD","LU1997245177.USD","LU2097828714.EUR","LU2148510915.USD","BK0012","LU1064130708.USD","BK0183","LU2289578879.USD","LU1580142542.USD","LU0359201885.HKD","LU0359201612.USD","BK0196","LU1255011170.USD","LU2543165471.USD","LU2097828474.EUR","LU0405327148.USD","LU2328871848.SGD","600276","LU2495084118.USD","BK0028","BK0188","LU1328615791.USD","LU2580892862.HKD","BK1191","LU1820825898.SGD","LU1997245094.SGD","LU2097828631.EUR","LU2580892789.USD","01276","LU0405327494.USD","LU2097828557.USD","LU1655091616.SGD","BK0239","LU1023057109.AUD","LU1969619763.USD","BK0060","LU1064131003.USD","LU0359202008.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660287986","title":"创新药占比突破63%，恒瑞医药正在切换估值坐标","url":"https://stock-news.laohu8.com/highlight/detail?id=2660287986","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660287986?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 21:18","pubTimestamp":1787231927,"startTime":"0","endTime":"0","summary":"第二增长曲线成型","market":"us","thumbnail":"https://img3.gelonghui.com/379fa-d7a4da80-ba02-4346-b923-b6f91de39d15.jpg?guru_height=718&guru_width=1280&guru_size=129619","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/379fa-d7a4da80-ba02-4346-b923-b6f91de39d15.jpg?guru_height=718&guru_width=1280&guru_size=129619"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6195075","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU2495084118.USD","BK0188","LU1655091616.SGD","IBBQ","LU0405327148.USD","BK1574","LU2488822045.USD","LU2580892789.USD","LU1997245094.SGD","BK0012","LU2097828557.USD","MEDX","LU2148510915.USD","BK0196","LU1997245177.USD","LU1328615791.USD","LNGR","LU1146622755.USD","BK0183","LU1064131003.USD","LU1820825898.SGD","BK0028","LU0359202008.SGD","LU0405327494.USD","159992","LU0359201885.HKD","LU1580142542.USD","LU1997244956.HKD","LU2328871848.SGD","LU2580892862.HKD","LU1255011170.USD","LU2097828631.EUR","BK1191","LU1023057109.AUD","LU2543165471.USD","LU1781817850.SGD","LU2097828714.EUR","BK0060","LU2097828474.EUR","LU1969619763.USD","LU1064130708.USD","BK0239","LU0359201612.USD","01276","06978","LU2289578879.USD","LU2097828805.USD","BK1161","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660255282","title":"恒瑞医药(01276.HK)SHR-8203注射液获准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2660255282","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660255282?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 20:58","pubTimestamp":1787230680,"startTime":"0","endTime":"0","summary":"恒瑞医药(01276.HK) 公布，子公司北京盛迪收到国家药监局核准签发关于SHR-8203注射液的药物临床试验批准通知书，同意本品单药在晚期实体瘤中开展临床试验。至今，SHR-8203注射液累计研发投入约2,040万人民币。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-08-20 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250730181922236_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250730181922236_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1539666/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1539666/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2580892862.HKD","LU1997245177.USD","LU2495084118.USD","LU1997244956.HKD","LU2543165471.USD","LU1820825898.SGD","LU0359201612.USD","LU1023057109.AUD","LU0405327494.USD","BK0028","LU1580142542.USD","LU2097828474.EUR","LU2328871848.SGD","LU2097828714.EUR","LU1328615791.USD","LU1255011170.USD","LU0359202008.SGD","LU0405327148.USD","LU1064131003.USD","LU2097828631.EUR","BK0188","LU2488822045.USD","LU1064130708.USD","LU1655091616.SGD","BK1191","BK0183","LU0359201885.HKD","LU2097828557.USD","LU2148510915.USD","LU1997245094.SGD","01276","BK0012","BK0196","LU2097828805.USD","BK0060","LU1781817850.SGD","BK0239","LU2580892789.USD","600276","LU1969619763.USD","LU1146622755.USD","LU2289578879.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660286773","title":"恒瑞医药同日公告：一款1类新药获批上市，三款创新药齐获临床批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2660286773","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660286773?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 19:06","pubTimestamp":1787223967,"startTime":"0","endTime":"0","summary":"8月20日盘后，恒瑞医药（SH600276，股价49.50元，市值3285亿元）连发四份公告，宣布其自主研发的1类新药富马酸立康可泮（HRS-5965）胶囊获国家药监局批准上市，同时旗下三款创新药SHR-8203注射液、SHR-7012注射液、HRS-3095片分别获得药物临床试验批准通知书，研发管线再迎密集进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203847966733.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203847966733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2580892789.USD","IBBQ","LU1328615791.USD","LU1064131003.USD","LU0405327148.USD","LU1146622755.USD","BK0239","BK0060","LU0359201612.USD","LU2097828631.EUR","LU0359202008.SGD","BK0012","LNGR","01276","LU1997245094.SGD","LU2495084118.USD","LU2289578879.USD","06978","LU1580142542.USD","LU2580892862.HKD","BK0196","LU1064130708.USD","159992","LU1969619763.USD","BK1574","LU1997245177.USD","LU2097828714.EUR","LU0359201885.HKD","LU1655091616.SGD","LU1997244956.HKD","LU2488822045.USD","LU1781817850.SGD","LU0405327494.USD","BK0028","BK0188","LU1023057109.AUD","LU2097828805.USD","LU2148510915.USD","600276","BK0183","LU2097828474.EUR","MEDX","LU2543165471.USD","LU1820825898.SGD","LU1255011170.USD","BK1191","BK1161","LU2328871848.SGD","LU2097828557.USD","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143598499","title":"恒瑞医药自主研发1类创新药利康帕泛富马酸（HRS-5965）胶囊获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1143598499","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143598499?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 18:35","pubTimestamp":1787222114,"startTime":"0","endTime":"0","summary":"恒瑞医药宣布，其自主研发的1类创新药利康帕泛富马酸胶囊已正式获得国家药品监督管理局批准，准许上市销售。这一里程碑式的进展，标志着公司在创新药研发领域再度取得重大突破。据悉，该药物作为全新一代治疗产品，其获批上市有望为相关疾病患者提供全新的治疗选择。值得注意的是，利康帕泛富马酸胶囊从临床前研究到最终获批，历经了严格的科学验证与审评流程，其安全性、有效性及质量可控性均获得了监管部门的充分认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2580892862.HKD","LU1969619763.USD","LU2097828474.EUR","LU2580892789.USD","LU2097828557.USD","600276","LU2148510915.USD","LU0405327494.USD","LU2097828631.EUR","LU0359202008.SGD","LU1064131003.USD","BK0012","LU1328615791.USD","LU2543165471.USD","01276","BK0183","LU2495084118.USD","LU1997245177.USD","BK0188","LU1997245094.SGD","BK0060","LU2488822045.USD","BK0239","BK0196","LU2097828805.USD","LU2328871848.SGD","LU1064130708.USD","LU1655091616.SGD","LU1255011170.USD","LU0359201885.HKD","LU1023057109.AUD","BK0028","LU1146622755.USD","LU1580142542.USD","LU0405327148.USD","LU1820825898.SGD","BK1191","LU1781817850.SGD","LU2289578879.USD","LU2097828714.EUR","LU1997244956.HKD","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173056686","title":"恒瑞医药获批开展HRS-3095片ITP及AIHA适应症临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1173056686","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173056686?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 18:32","pubTimestamp":1787221966,"startTime":"0","endTime":"0","summary":"2026年8月20日，恒瑞医药公告称，其子公司成都盛迪医药有限公司已收到国家药品监督管理局核准签发的HRS-3095片《药物临床试验批准通知书》，同意该药物用于原发免疫性血小板减少症和自身免疫性溶血性贫血的临床试验。此次临床试验申请受理号为CXHL2600653、CXHL2600654、CXHL2600655及CXHL2600656，受理日期为2026年6月3日。恒瑞医药表示将按监管要求推进项目进展，并及时披露后续信息。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660764283","title":"恒瑞医药(01276.HK) ：SHR-7012 注射液拟用于治疗皮肤型红斑狼疮获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2660764283","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660764283?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 18:22","pubTimestamp":1787221372,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0359201885.HKD","LU1023057109.AUD","LU0359201612.USD","01276","LU0359202008.SGD","LU2543165471.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161547637","title":"恒瑞医药获批开展SHR-7012注射液临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1161547637","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161547637?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 18:20","pubTimestamp":1787221230,"startTime":"0","endTime":"0","summary":"2026年8月20日，江蘇恒瑞醫藥股份有限公司公告称，其子公司广东恒瑞医药有限公司已收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意对创新药物SHR-7012注射液开展临床试验。公告显示，SHR-7012拟用于治疗皮肤型红斑狼疮，受理号为CXSL2600557。SHR-7012为公司自主研发，目前国内外暂无同靶点药物获批上市。恒瑞医药提示，药品从临床试验至最终上市尚需经过多环节审批，存在不确定性风险。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161718052","title":"恒瑞医药(01276)获批开展SHR-8203注射液晚期实体瘤临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1161718052","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161718052?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 18:15","pubTimestamp":1787220936,"startTime":"0","endTime":"0","summary":"2026年8月20日，恒瑞医药(01276)公告称，其子公司北京盛迪医药有限公司已收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意在晚期实体瘤患者中开展SHR-8203注射液的单药临床试验。批准对应受理号为CXSL2600576。\nSHR-8203注射液为公司自主研发的创新型抗肿瘤药物，拟用于治疗晚期实体瘤。截至目前，该项目累计研发投入约2,040万元（未经审计）。经公司查询，国内外尚无同类药物上市。\n公司提示，药物上市仍需完成临床试验并通过国家药监局后续审评审批，研发及上市周期存在不确定性。公司将按相关法规推进项目进展，并及时披露后续信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660283172","title":"恒瑞医药(01276.HK)：SHR-8203 注射液获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2660283172","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660283172?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 18:15","pubTimestamp":1787220934,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","LU0359201885.HKD","01276","LU0359201612.USD","LU2543165471.USD","LU0359202008.SGD","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660283161","title":"恒瑞医药富马酸立康可泮胶囊获药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2660283161","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660283161?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 17:59","pubTimestamp":1787219960,"startTime":"0","endTime":"0","summary":"8月20日，恒瑞医药发布公告称，公司子公司成都盛迪医药有限公司近日收到国家药品监督管理局的通知，批准公司自主研发的1类新药富马酸立康可泮（HRS-5965）胶囊上市。根据公告，富马酸立康可泮胶囊是一种补体因子B抑制剂，作为靶向补体旁路途径的近端补体抑制，其通过抑制旁路途径的异常激活与补体扩增循环，从机制层面同时抑制血管内溶血和血管外溶血，提升血红蛋白水平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203847895762.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203847895762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1023057109.AUD","LU2289578879.USD","LU0359202008.SGD","LU0359201612.USD","LU1328615791.USD","LU2580892789.USD","LU2097828631.EUR","LU1255011170.USD","LU1064130708.USD","LU2097828805.USD","LU2580892862.HKD","LU0405327494.USD","LU0359201885.HKD","LU1580142542.USD","BK0188","LU0405327148.USD","LU1997244956.HKD","LU2097828714.EUR","LU1146622755.USD","01276","BK0196","LU2148510915.USD","LU1969619763.USD","LU1997245177.USD","600276","LU1997245094.SGD","BK1191","BK0183","BK0028","LU1781817850.SGD","LU2097828557.USD","LU2097828474.EUR","BK0060","BK0012","LU1655091616.SGD","LU2488822045.USD","LU1820825898.SGD","LU2328871848.SGD","LU2543165471.USD","LU2495084118.USD","LU1064131003.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660407083","title":"恒瑞医药：子公司3款药物获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2660407083","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660407083?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 17:02","pubTimestamp":1787216520,"startTime":"0","endTime":"0","summary":"8月20日，恒瑞医药（600276/01276）发布公告，公司子公司北京盛迪、广东恒瑞及成都盛迪分别收到国家药监局核准签发的《药物临床试验批准通知书》，涉及SHR-8203注射液、SHR-7012注射液及HRS-3095片三款药物，均将于近期开展临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203847831616.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203847831616.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0359202008.SGD","LU2097828557.USD","LU2580892789.USD","LU0405327148.USD","LU1997244956.HKD","LU2328871848.SGD","LU2148510915.USD","LU1255011170.USD","LU2580892862.HKD","LU2097828474.EUR","LU1997245094.SGD","LU1781817850.SGD","LU1064131003.USD","LU1328615791.USD","BK0028","LU1969619763.USD","LU2097828714.EUR","LU2495084118.USD","LU1023057109.AUD","LU2097828631.EUR","LU2097828805.USD","LU1064130708.USD","BK0012","LU1580142542.USD","BK0183","LU2488822045.USD","LU1146622755.USD","LU0359201612.USD","BK0060","01276","LU0359201885.HKD","LU1997245177.USD","BK0239","BK0196","LU1655091616.SGD","LU2289578879.USD","LU0405327494.USD","BK0188","BK1191","LU1820825898.SGD","LU2543165471.USD","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660402211","title":"恒瑞医药：HRS-3095片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2660402211","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660402211?lang=zh_cn&edition=fundamental","pubTime":"2026-08-20 16:41","pubTimestamp":1787215260,"startTime":"0","endTime":"0","summary":"南财智讯8月20日电，恒瑞医药公告，HRS-3095片收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意开展原发免疫性血小板减少症（ITP）和自身免疫性溶血性贫血（AIHA）的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203847797826.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203847797826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0012","BK0060","LU1997244956.HKD","LU2488822045.USD","BK1191","LU0359201612.USD","LU1997245094.SGD","LU1023057109.AUD","LU1997245177.USD","BK0183","LU2097828714.EUR","MDTX","BMED","BK0239","LU1146622755.USD","LU2097828631.EUR","LU2097828557.USD","LU0405327148.USD","01276","BK0028","LU1969619763.USD","IBBJ","LU0359201885.HKD","LU1255011170.USD","LU1781817850.SGD","LU2328871848.SGD","LU2289578879.USD","LU2543165471.USD","BK0196","LU1580142542.USD","PSYK","BK0188","LU2148510915.USD","IBBQ","LU1064131003.USD","LU2580892862.HKD","LU2580892789.USD","LU0359202008.SGD","600276","LU1820825898.SGD","LU2097828474.EUR","LU2495084118.USD","LU1328615791.USD","LU2097828805.USD","LU1064130708.USD","LU0405327494.USD","LU1655091616.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}